Pancreas NeoplasmNCT07831694
Postoperative Outcomes After Partial Duodenopancreatectomy Versus Total Pancreatectomy
An observational study of Pancreas Neoplasm, run by Cantonal Hospital of St. Gallen.
Trial summary
The goal of this observational study is to compare short-term outcomes after partial pancreatoduodenectomy and total pancreatectomy in adults undergoing elective surgery for pancreatic or periampullary neoplasms in Switzerland. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Pancreas Neoplasm
- How many people
- 3,602 participants
- Where
- No sites listed yet
- Study dates
- Jan 2013to Mar 2026
- How long will I take part?
- 90 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population comprises adults aged 20 years or older who underwent elective partial pancreatoduodenectomy or total pancreatectomy for a pancreatic or periampullary neoplasm at a Swiss hospital between 2013 and 2022. Patients undergoing emergency surgery, those with incomplete records, and those undergoing additional pancreatic resections were excluded. The study is based exclusively on anonymised data from the Swiss national inpatient database.
Who may be able to join
- patients >20 years
- peripancreatic / pancreatic neoplasm
- total pancreatectomy or partial duodenopancreatectomy
Who cannot join
- patients <20 years
- emergency admission
- other pancreatic surgery
- other disease than peripancreatic neoplasm
- incomplete documentation
About this study
Official title: Postoperative Outcomes After Partial Duodenopancreatectomy Versus Total Pancreatectomy - a Nationwide Propensity Score Matched and Mediation Analysis
The goal of this observational study is to compare short-term outcomes after partial pancreatoduodenectomy and total pancreatectomy in adults undergoing elective surgery for pancreatic or periampullary neoplasms in Switzerland. The main questions it aims to answer are: Is total pancreatectomy associated with higher in-hospital mortality than partial pancreatoduodenectomy? Do postoperative complications and failure to rescue differ between the two procedures? Researchers will compare patients undergoing total pancreatectomy with those undergoing partial pancreatoduodenectomy to assess differences in mortality, postoperative complications and failure to rescue. Propensity score matching and mediation analysis will be used to reduce potential bias and evaluate the independent association of surgical procedure with mortality and failure to rescue.
This retrospective study uses anonymised data from the Swiss national inpatient database between 2013 and 2022. Participants will not receive any study-related intervention and will not be contacted.
- Conditions
- Pancreas Neoplasm
- Keywords
- Pancreas neoplasm, Partial duodenopancreatectomy, Total pancreatectomy, Failure to rescue
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients undergoing PD for pancreatic neoplasm | Not described | |
| Patients undergoing TP for pancreatic neoplasm | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality Rate
In-hospital mortality
Measured: Perioperatively
Secondary outcomes (2)
Complications
Rate of postoperative complications
Measured: Perioperatively
Failure to rescue Rate
Mortality after major complications
Measured: Perioperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2026
- Study startJan 2013
- Primary completionDec 2022
- Study completionMar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreas NeoplasmStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,602 participants (actual)
- Target duration
- 90 Days
Sponsor and investigators
- Lead sponsor
- Cantonal Hospital of St. Gallen
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Marie Klein, Cantonal Hospital of St. Gallen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07831694
- Sponsor's protocol ID
- TPvsPD
- Status last verified
- Oct 2026
- First submitted
- 10 Sep 2026
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Postoperative Outcomes After Partial Duodenopancreatectomy Versus Total Pancreatectomy - a Nationwide Propensity Score Matched and Mediation Analysis
- ClinicalTrials.gov ID
- NCT07831694
- Acronym / sponsor ID
- TPvsPD
- Conditions
- Pancreas Neoplasm
- Keywords
- Pancreas neoplasm, Partial duodenopancreatectomy, Total pancreatectomy, Failure to rescue
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,602 participants (actual)
- Lead sponsor
- Cantonal Hospital of St. GallenUniversity, hospital or other
- Study start
- Jan 2013 (actual)
- Primary completion
- Dec 2022 (actual)
- Study completion
- Mar 2026 (actual)
- First posted
- 21 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to compare short-term outcomes after partial pancreatoduodenectomy and total pancreatectomy in adults undergoing elective surgery for pancreatic or periampullary neoplasms in Switzerland. The main questions it aims to answer are: Is total pancreatectomy associated with higher in-hospital mortality than partial pancreatoduodenectomy? Do postoperative complications and failure to rescue differ between the two procedures? Researchers will compare patients undergoing total pancreatectomy with those undergoing partial pancreatoduodenectomy to assess differences in mortality, postoperative complications and failure to rescue. Propensity score matching and mediation analysis will be used to reduce potential bias and evaluate the independent association of surgical procedure with mortality and failure to rescue.
This retrospective study uses anonymised data from the Swiss national inpatient database between 2013 and 2022. Participants will not receive any study-related intervention and will not be contacted.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 90 Days
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients undergoing PD for pancreatic neoplasm | – | – |
| Patients undergoing TP for pancreatic neoplasm | – | – |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population comprises adults aged 20 years or older who underwent elective partial pancreatoduodenectomy or total pancreatectomy for a pancreatic or periampullary neoplasm at a Swiss hospital between 2013 and 2022. Patients undergoing emergency surgery, those with incomplete records, and those undergoing additional pancreatic resections were excluded. The study is based exclusively on anonymised data from the Swiss national inpatient database.
Key inclusion criteria (3 listed)
- patients >20 years
- peripancreatic / pancreatic neoplasm
- total pancreatectomy or partial duodenopancreatectomy
Key exclusion criteria (5 listed)
- patients <20 years
- emergency admission
- other pancreatic surgery
- other disease than peripancreatic neoplasm
- incomplete documentation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Mortality Rate
Time frame: Perioperatively
In-hospital mortality
2 secondary outcomes
Complications
Time frame: Perioperatively
Failure to rescue Rate
Time frame: Perioperatively
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Pancreas Neoplasm
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreas Neoplasm, run by Cantonal Hospital of St. Gallen.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality Rate (time frame: Perioperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.